Cetuximab works by blocking EGFR dimerization and when combined with EAIO45 showed antiproliferative responses both in vivo and in vitro models of lung cancer driven by EGFR L858R/T790M and by EGFR L858R/T790M/C797S mutations [12,13]. This evidence concerns the gene EGFR and lung cancer.